Stifel Downgrades IDEAYA Biosciences to Hold, Lowers Price Target to $13
Stifel analyst Benjamin Burnett downgrades IDEAYA Biosciences (NASDAQ:IDYA) from Buy to Hold and lowers the price target from $16 to $13.
U.S. Stocks Edge Lower; NY Empire State Manufacturing Index Drops In August
U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday.
Recap: IDEAYA Biosciences Q2 Earnings
IDEAYA Biosciences (NASDAQ:IDYA) reported its Q2 earnings results on Monday, August 15, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings
IDEAYA Biosciences missed estimated earnings by 9.62%, reporting an EPS of $-0.57 versus an estimate of $-0.52.
Revenue was down $2.90 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.05
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc.
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase…
FDA Grants Orphan Drug Designation For IDEAYA’s Darovasertib For Uveal Melanoma
The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.
IDEAYA Biosciences Granted FDA Orphan Drug Designation Wednesday for Darovasertib for Treatment of Uveal Melanoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=873322
